Log in

NYSE:AGNAllergan Competitors & Alternatives

Notice: This company has been marked as potentially delisted and may not be actively trading.
$193.02
0.00 (0.00 %)
(As of 05/8/2020)
Add
Compare
Today's Range
$191.64
Now: $193.02
$193.38
50-Day Range
$184.04
MA: $190.89
$193.89
52-Week Range
$114.27
Now: $193.02
$202.21
Volume12.44 million shs
Average Volume4.01 million shs
Market Capitalization$63.50 billion
P/E RatioN/A
Dividend Yield1.53%
Beta1.2

Competitors

Allergan (NYSE:AGN) Vs. JNJ, MRK, PFE, LLY, ABBV, and BMY

Should you be buying AGN stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Allergan, including Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Allergan (NYSE:AGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Johnson & Johnson and Allergan, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson041202.75
Allergan010002.00

Johnson & Johnson presently has a consensus target price of $163.8571, suggesting a potential upside of 15.09%. Allergan has a consensus target price of $184.8850, suggesting a potential downside of 4.21%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, equities analysts clearly believe Johnson & Johnson is more favorable than Allergan.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Allergan has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Earnings and Valuation

This table compares Johnson & Johnson and Allergan's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion4.57$15.12 billion$8.6816.40
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94

Johnson & Johnson has higher revenue and earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and Allergan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson24.47%39.71%15.27%
Allergan-15.44%8.46%5.31%

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.8%. Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Allergan pays out 16.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 57 consecutive years and Allergan has raised its dividend for 2 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

68.4% of Johnson & Johnson shares are held by institutional investors. Comparatively, 83.9% of Allergan shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Allergan shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Johnson & Johnson beats Allergan on 13 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Allergan (NYSE:AGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.2%. Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Allergan pays out 16.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 8 consecutive years and Allergan has raised its dividend for 2 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Allergan has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Allergan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.21.10%52.46%16.67%
Allergan-15.44%8.46%5.31%

Earnings & Valuation

This table compares Merck & Co., Inc. and Allergan's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.13$9.84 billion$5.1914.78
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94

Merck & Co., Inc. has higher revenue and earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Merck & Co., Inc. and Allergan, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Allergan010002.00

Merck & Co., Inc. presently has a consensus target price of $94.1538, indicating a potential upside of 22.71%. Allergan has a consensus target price of $184.8850, indicating a potential downside of 4.21%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, research analysts plainly believe Merck & Co., Inc. is more favorable than Allergan.

Institutional and Insider Ownership

74.3% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 83.9% of Allergan shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of Allergan shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Allergan on 13 of the 17 factors compared between the two stocks.

Allergan (NYSE:AGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Allergan and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allergan-15.44%8.46%5.31%
Pfizer31.17%25.76%9.91%

Dividends

Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. Allergan pays out 16.8% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Allergan has raised its dividend for 2 consecutive years and Pfizer has raised its dividend for 10 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Allergan has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Allergan and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allergan010002.00
Pfizer08402.33

Allergan presently has a consensus price target of $184.8850, indicating a potential downside of 4.21%. Pfizer has a consensus price target of $38.6083, indicating a potential upside of 14.12%. Given Pfizer's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Allergan.

Insider & Institutional Ownership

83.9% of Allergan shares are held by institutional investors. Comparatively, 70.2% of Pfizer shares are held by institutional investors. 0.1% of Allergan shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Allergan and Pfizer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94
Pfizer$51.75 billion3.63$16.27 billion$2.9511.47

Pfizer has higher revenue and earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Allergan on 11 of the 16 factors compared between the two stocks.

Allergan (NYSE:AGN) and Eli Lilly And Co (NYSE:LLY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Dividends

Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 1.8%. Allergan pays out 16.8% of its earnings in the form of a dividend. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Allergan has raised its dividend for 2 consecutive years and Eli Lilly And Co has raised its dividend for 5 consecutive years. Eli Lilly And Co is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

83.9% of Allergan shares are owned by institutional investors. Comparatively, 77.3% of Eli Lilly And Co shares are owned by institutional investors. 0.1% of Allergan shares are owned by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Allergan and Eli Lilly And Co, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allergan010002.00
Eli Lilly And Co04712.75

Allergan presently has a consensus target price of $184.8850, suggesting a potential downside of 4.21%. Eli Lilly And Co has a consensus target price of $169.7273, suggesting a potential upside of 3.90%. Given Eli Lilly And Co's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly And Co is more favorable than Allergan.

Valuation and Earnings

This table compares Allergan and Eli Lilly And Co's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94
Eli Lilly And Co$22.32 billion7.00$8.32 billion$6.0427.05

Eli Lilly And Co has higher revenue and earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Eli Lilly And Co, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Allergan has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Profitability

This table compares Allergan and Eli Lilly And Co's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allergan-15.44%8.46%5.31%
Eli Lilly And Co23.97%194.18%15.11%

Summary

Eli Lilly And Co beats Allergan on 14 of the 18 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Allergan (NYSE:AGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Risk and Volatility

AbbVie has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Allergan has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

72.4% of AbbVie shares are owned by institutional investors. Comparatively, 83.9% of Allergan shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.1% of Allergan shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 4.9%. Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Allergan pays out 16.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 47 consecutive years and Allergan has increased its dividend for 2 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings & Valuation

This table compares AbbVie and Allergan's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion4.30$7.88 billion$8.9410.83
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94

AbbVie has higher revenue and earnings than Allergan. AbbVie is trading at a lower price-to-earnings ratio than Allergan, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AbbVie and Allergan, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie031402.82
Allergan010002.00

AbbVie presently has a consensus target price of $106.80, suggesting a potential upside of 10.30%. Allergan has a consensus target price of $184.8850, suggesting a potential downside of 4.21%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts plainly believe AbbVie is more favorable than Allergan.

Profitability

This table compares AbbVie and Allergan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie24.77%-169.80%18.52%
Allergan-15.44%8.46%5.31%

Summary

AbbVie beats Allergan on 12 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Allergan (NYSE:AGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Institutional and Insider Ownership

74.2% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 83.9% of Allergan shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Allergan shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Bristol-Myers Squibb and Allergan's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion4.97$3.44 billion$4.6912.25
Allergan$16.09 billion3.95$-5,271,000,000.00$17.6410.94

Bristol-Myers Squibb has higher revenue and earnings than Allergan. Allergan is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and Allergan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb3.08%30.06%10.96%
Allergan-15.44%8.46%5.31%

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 3.1%. Allergan pays an annual dividend of $2.96 per share and has a dividend yield of 1.5%. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Allergan pays out 16.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 10 consecutive years and Allergan has raised its dividend for 2 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of recent ratings for Bristol-Myers Squibb and Allergan, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031102.79
Allergan010002.00

Bristol-Myers Squibb presently has a consensus target price of $68.1667, indicating a potential upside of 18.70%. Allergan has a consensus target price of $184.8850, indicating a potential downside of 4.21%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Allergan.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Allergan has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Allergan on 13 of the 17 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$142.37flat$375.09 billion$82.06 billion18.83Upcoming Earnings
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.3$76.73flat$193.67 billion$46.84 billion19.43
Pfizer logo
PFE
Pfizer
2.7$33.83flat$187.92 billion$51.75 billion12.08
Eli Lilly And Co logo
LLY
Eli Lilly And Co
2.1$163.36flat$156.25 billion$22.32 billion27.00Insider Selling
AbbVie logo
ABBV
AbbVie
2.7$96.83flat$142.99 billion$33.27 billion17.14
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$57.43flat$129.95 billion$26.15 billion70.90
Zoetis logo
ZTS
Zoetis
1.9$137.10flat$65.11 billion$6.26 billion40.93
Royalty Pharma logo
RPRX
Royalty Pharma
1.1$47.64flat$28.36 billionN/A0.00Analyst Report
Horizon Therapeutics logo
HZNP
Horizon Therapeutics
1.7$57.23flat$10.92 billion$1.30 billion20.22
Mylan logo
MYL
Mylan
1.6$16.10flat$8.32 billion$11.50 billion134.18
Perrigo logo
PRGO
Perrigo
1.9$55.17flat$7.52 billion$4.84 billion40.27
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.1$106.60flat$5.90 billion$2.16 billion22.16
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$24.03flat$4.28 billion$114.62 million-9.21Insider Selling
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$57.80flat$2.43 billion$421.03 million-2,888.56Analyst Upgrade
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.50flat$1.89 billion$306.49 million18.75
Zogenix logo
ZGNX
Zogenix
2.0$27.24flat$1.51 billion$3.65 million-2.89Analyst Downgrade
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$24.25flat$1.27 billion$392.76 million11.18
Endo International logo
ENDP
Endo International
1.5$3.44flat$790.18 million$2.91 billion-2.82
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.3$23.02flat$753.27 million$15.96 million-6.71
Omeros logo
OMER
Omeros
1.5$13.61flat$741.89 million$111.81 million-7.87
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
1.9$4.22flat$422.70 million$111.39 million-46.89Heavy News Reporting
Lannett logo
LCI
Lannett
1.6$5.74flat$231.61 million$655.41 million-7.00High Trading Volume
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$5.22flat$225.14 million$16.54 million-1.50
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
2.4$3.18flat$48.28 million$47.53 million-10.60
VIVUS logo
VVUS
VIVUS
1.2$0.53flat$9.45 million$69.76 million-0.20
This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.